{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T09:20:52Z","timestamp":1766049652920},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,5,22]],"date-time":"2021-05-22T00:00:00Z","timestamp":1621641600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,5,22]],"date-time":"2021-05-22T00:00:00Z","timestamp":1621641600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Neurol"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Ala97Ser transthyretin amyloidosis-associated polyneuropathy (ATTRA97S-PN) is a rare form of inherited polyneuropathy, usually manifesting with late-onset (&gt;\u200950) progressive polyneuropathy. This mutation is mostly prevalent in Taiwanese and Han-Chinese individuals. The aim of this study was to describe the clinical and comprehensive neurophysiological profiles of ATTRA97S-PN in Thai patients.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>The clinical profiles and serial neurophysiologic studies (nerve conduction study (NCS), quantitative sensory test (QST), and comprehensive autonomic function test (AFT)) of symptomatic ATTRA97S-PN patients who had been followed-up at King Chulalongkorn Memorial Hospital during 2010\u20132020 were retrospectively reviewed.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Nine symptomatic patients (55.6\u2009% were male) from four unrelated families were included. All were Thais of mixed Thai Chinese descent. The mean age of onset was 48.3 (32\u201360) years. The mean age at diagnosis was 54.8 (33\u201366) years. Three patients developed early-onset (&lt;\u200940y) polyneuropathy. The mean Neuropathy Impairment Score was 41.33 (10\u201392) at diagnosis. Sensory (9\/9) and autonomic (9\/9) neuropathies were more frequent than motor neuropathy (5\/9), which appeared in the late stage of disease. Hypoesthesia in the feet, and gastrointestinal autonomic symptoms were frequently reported as the initial symptoms. The course of neuropathy progressed over years to decades. The worsening of neuropathy tended to progress faster once motor nerves were affected in both clinical and neurophysiological aspects. Concurrent cardiac amyloidosis was found in 6\/9 patients. NCS showed length-dependent sensorimotor axonal polyneuropathy in 5\/9 patients, and median neuropathy at the wrist (mostly bilateral) in 7\/9 patients. QST showed abnormalities in the vibratory detection threshold, the cold detection threshold and the heat pain sensation in 8\/9, 8\/9 and 7\/7 tested patients, respectively. AFT results were abnormal in all. The mean composite autonomic severity score was 5 (3\u20139).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>This clinical study is the first of ATTRA97S-PN in Thai patients. The mixed polyneuropathy-cardiopathy phenotype was the most common manifestation. In this cohort, the age of onset was lower, and the course of neuropathy was relatively longer, than that in previous studies. Some patients may develop early-onset polyneuropathy. This mutation has not yet been documented in any population other than Han Chinese-related populations, probably suggesting a founder effect. Further studies are warranted.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12883-021-02243-3","type":"journal-article","created":{"date-parts":[[2021,5,22]],"date-time":"2021-05-22T04:21:56Z","timestamp":1621657316000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Ala97Ser transthyretin amyloidosis-associated polyneuropathy, clinical and neurophysiological profiles in a Thai cohort"],"prefix":"10.1186","volume":"21","author":[{"given":"Nath","family":"Pasutharnchat","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chamaiporn","family":"Taychargumpoo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yongkasem","family":"Vorasettakarnkij","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jakkrit","family":"Amornvit","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,5,22]]},"reference":[{"key":"2243_CR1","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1007\/s00415-017-8708-4","volume":"265","author":"V Plante-Bordeneuve","year":"2018","unstructured":"Plante-Bordeneuve V. Transthyretin familial amyloid polyneuropathy: an update. J Neurol. 2018;265:976\u201383.","journal-title":"J Neurol"},{"key":"2243_CR2","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1111\/ane.13035","volume":"139","author":"J Finsterer","year":"2019","unstructured":"Finsterer J, Iglseder S, Wanschitz J, Topakian R, L\u00f6scher WN, Grisold W. Hereditary transthyretin-related amyloidosis. Acta Neurol Scand. 2019;139:92\u2013105.","journal-title":"Acta Neurol Scand"},{"key":"2243_CR3","unstructured":"Rowczenio D, Wechalekar A. Mutations in hereditary amyloidosis. 2015 http:\/\/amyloidosismutations.com\/mut-attr.php. Accessed 30 Mar 2021."},{"key":"2243_CR4","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/s13023-019-1000-1","volume":"14","author":"M Waddington-Cruz","year":"2019","unstructured":"Waddington-Cruz M, Schmidt H, Botteman MF, Carter JA, Stewart M, Hopps M, et al. Epidemiological and clinical characteristics of symptomatic hereditary transthyretin amyloid polyneuropathy: a global case series. Orphanet J Rare Dis. 2019;14:34.","journal-title":"Orphanet J Rare Dis"},{"key":"2243_CR5","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-019-09688-0","author":"D Adams","year":"2020","unstructured":"Adams D, Ando Y, Beir\u00e3o JM, Coelho T, Gertz MA, Gillmore JD, et al. Expert consensus recommendations to improve diagnosis of ATTR amyloidosis with polyneuropathy. J Neurol. 2020. doi: https:\/\/doi.org\/10.1007\/s00415-019-09688-0.","journal-title":"J Neurol"},{"key":"2243_CR6","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1002\/acn3.778","volume":"6","author":"HC Chao","year":"2019","unstructured":"Chao HC, Liao YC, Liu YT, Guo YC, Chang FP, Lee YC, et al. Clinical and genetic profiles of hereditary transthyretin amyloidosis in Taiwan. Ann Clin Transl Neurol. 2019;6:913\u201322.","journal-title":"Ann Clin Transl Neurol"},{"key":"2243_CR7","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1186\/s12883-017-0957-4","volume":"17","author":"HC Hsu","year":"2017","unstructured":"Hsu HC, Liao MF, Hsu JL, Lo AL, Kuo HC, Lyu RK, et al. Phenotypic expressions of hereditary transthyretin Ala97Ser related amyloidosis (ATTR) in Taiwanese. BMC Neurol. 2017;17:178.","journal-title":"BMC Neurol"},{"key":"2243_CR8","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1002\/ana.24438","volume":"78","author":"CC Chao","year":"2015","unstructured":"Chao CC, Huang CM, Chiang HH, Luo KR, Kan HW, Yang NC, et al. Sudomotor innervation in transthyretin amyloid neuropathy: Pathology and functional correlates. Ann Neurol. 2015;78:272\u201383.","journal-title":"Ann Neurol"},{"key":"2243_CR9","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1212\/WNL.0b013e3181ec7fda","volume":"75","author":"NC Yang","year":"2010","unstructured":"Yang NC, Lee MJ, Chao CC, Chuang YT, Lin WM, Chang MF, et al. Clinical presentations and skin denervation in amyloid neuropathy due to transthyretin Ala97Ser. Neurology. 2010;75:532\u20138.","journal-title":"Neurology"},{"key":"2243_CR10","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.jns.2007.10.011","volume":"267","author":"YT Liu","year":"2008","unstructured":"Liu YT, Lee YC, Yang CC, Chen ML, Lin KP. Transthyretin Ala97Ser in Chinese-Taiwanese patients with familial amyloid polyneuropathy: genetic studies and phenotype expression. J Neurol Sci. 2008;267:91\u20139.","journal-title":"J Neurol Sci"},{"key":"2243_CR11","doi-asserted-by":"publisher","first-page":"116424","DOI":"10.1016\/j.jns.2019.116424","volume":"405","author":"PJB Dyck","year":"2019","unstructured":"Dyck PJB, Gonz\u00e1lez-Duarte A, Obici L, Polydefkis M, Wiesman JF, Antonino I, et al. Development of measures of polyneuropathy impairment in hATTR amyloidosis: From NIS to mNIS + 7. J Neurol Sci. 2019;405:116424.","journal-title":"J Neurol Sci"},{"key":"2243_CR12","doi-asserted-by":"publisher","first-page":"e006075","DOI":"10.1161\/CIRCHEARTFAILURE.119.006075","volume":"12","author":"MS Maurer","year":"2019","unstructured":"Maurer MS, Bokhari S, Damy T, Dorbala S, Drachman BM, Fontana M, et al. Expert consensus recommendations for the suspicion and diagnosis of transthyretin cardiac amyloidosis. Circ Heart Fail. 2019;12:e006075.","journal-title":"Circ Heart Fail"},{"key":"2243_CR13","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1007\/s12350-019-01761-5","volume":"27","author":"S Dorbala","year":"2020","unstructured":"Dorbala S, Ando Y, Bokhari S, Dispenzieri A, Falk RH, Ferrari VA, et al. ASNC\/AHA\/ASE\/EANM\/HFSA\/ISA\/SCMR\/SNMMI expert consensus recommendations for multimodality imaging in cardiac amyloidosis: Part 2 of 2-Diagnostic criteria and appropriate utilization. J Nucl Cardiol. 2020;27:659\u2013673.","journal-title":"J Nucl Cardiol"},{"key":"2243_CR14","doi-asserted-by":"crossref","unstructured":"Low PA. Composite autonomic scoring scale for laboratory quantification of generalized autonomic failure. Mayo Clin Proc. 1993;68:748 \u2013 52.","DOI":"10.1016\/S0025-6196(12)60631-4"},{"key":"2243_CR15","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1002\/mus.21332","volume":"40","author":"DH Kim","year":"2009","unstructured":"Kim DH, Zeldenrust SR, Low PA, Dyck PJ. Quantitative sensation and autonomic test abnormalities in transthyretin amyloidosis polyneuropathy. Muscle Nerve. 2009;40:363\u201370.","journal-title":"Muscle Nerve"},{"key":"2243_CR16","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1016\/j.jfma.2019.08.027","volume":"119","author":"HJ Lai","year":"2020","unstructured":"Lai HJ, Huang KC, Liang YC, Chien KL, Lee MJ, Hsieh ST, et al. Cardiac manifestations and prognostic implications of hereditary transthyretin amyloidosis associated with transthyretin Ala97Ser. J Formos Med Assoc. 2020;119:693\u2013700.","journal-title":"J Formos Med Assoc"},{"key":"2243_CR17","doi-asserted-by":"crossref","unstructured":"Du K, Li F, Wang H, Miao Y, Lv H, Zhang W, et al. Hereditary transthyretin amyloidosis in mainland China: a unicentric retrospective study. Ann Clin Transl Neurol. 2021.","DOI":"10.1002\/acn3.51328"},{"key":"2243_CR18","doi-asserted-by":"publisher","first-page":"2616","DOI":"10.1097\/CM9.0000000000001094","volume":"133","author":"L Liu","year":"2020","unstructured":"Liu L, Li XB, Hu ZM, Huang SX, Tang BS, Zhang RX. Clinical and genetic features of transthyretin-related familial amyloid polyneuropathy in China. Chin Med J (Engl). 2020;133:2616\u20138.","journal-title":"Chin Med J (Engl)"},{"key":"2243_CR19","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/j.jocn.2018.10.040","volume":"60","author":"Z Yuan","year":"2019","unstructured":"Yuan Z, Guo L, Liu X, Xiao X, Jiao B, Wang J, et al. Familial amyloid polyneuropathy with chronic paroxysmal dry cough in Mainland China: A Chinese family with a proven heterozygous missense mutation c.349G > T in the transthyretin gene. J Clin Neurosci. 2019;60:164\u20136.","journal-title":"J Clin Neurosci"},{"key":"2243_CR20","doi-asserted-by":"publisher","first-page":"4911","DOI":"10.1007\/s12035-017-0694-0","volume":"55","author":"Q Chen","year":"2018","unstructured":"Chen Q, Yuan L, Deng X, Yang Z, Zhang S, Deng S, et al. A Missense Variant p.Ala117Ser in the transthyretin gene of a Han Chinese family with familial amyloid polyneuropathy. Mol Neurobiol. 2018;55:4911\u20137.","journal-title":"Mol Neurobiol"},{"key":"2243_CR21","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1080\/13506129.2019.1582479","volume":"26","author":"SC Low","year":"2019","unstructured":"Low SC, Tan CY, Md Sari NA, Ahmad-Annuar A, Wong KT, Lin KP, et al. Ala97Ser mutation is common among ethnic Chinese Malaysians with transthyretin familial amyloid polyneuropathy. Amyloid. 2019;26:7\u20138.","journal-title":"Amyloid"},{"key":"2243_CR22","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1002\/1098-1004(200008)16:2<180::AID-HUMU19>3.0.CO;2-A","volume":"16","author":"HJ Lachmann","year":"2000","unstructured":"Lachmann HJ, Booth DR, Bybee A, Hawkins PN. Transthyretin Ala97Ser is associated with familial amyloidotic polyneuropathy in a Chinese-Taiwanese family. Hum Mutat. 2000;16:180.","journal-title":"Hum Mutat"},{"key":"2243_CR23","doi-asserted-by":"publisher","first-page":"282","DOI":"10.3109\/13506129909007341","volume":"6","author":"N Tachibana","year":"1999","unstructured":"Tachibana N, Tokuda T, Yoshida K, Taketomi T, Nakazato M, Li YF, et al. Usefulness of MALDI\/TOF mass spectrometry of immunoprecipitated serum variant transthyretin in the diagnosis of familial amyloid polyneuropathy. Amyloid. 1999;6:282\u20138.","journal-title":"Amyloid"},{"key":"2243_CR24","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1002\/mus.20689","volume":"35","author":"V Heldestad","year":"2007","unstructured":"Heldestad V, Nordh E. Quantified sensory abnormalities in early genetically verified transthyretin amyloid polyneuropathy. Muscle Nerve. 2007;35:189\u201395.","journal-title":"Muscle Nerve"},{"key":"2243_CR25","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1186\/s12883-021-02094-y","volume":"21","author":"X Lin","year":"2021","unstructured":"Lin X, Yarlas A, Vera-Llonch M, Baranwal N, Biber J, Brown D, et al. Rate of neuropathic progression in hereditary transthyretin amyloidosis with polyneuropathy and other peripheral neuropathies: a systematic review and meta-analysis. BMC Neurol. 2021;21:70.","journal-title":"BMC Neurol"},{"issue":"Suppl 1","key":"2243_CR26","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1080\/13506129.2003.12088566","volume":"10","author":"G Sobue","year":"2003","unstructured":"Sobue G, Koike H, Misu K, Hattori N, Yamamoto M, Ikeda S, et al. Clinicopathologic and genetic features of early- and late-onset FAP type I (FAP ATTR Val30Met) in Japan. Amyloid. 2003;10 Suppl 1:32\u20138.","journal-title":"Amyloid"},{"key":"2243_CR27","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1136\/jnnp-2017-316657","volume":"89","author":"D Santos","year":"2018","unstructured":"Santos D, Santos MJ, Alves-Ferreira M, Coelho T, Sequeiros J, Alonso I, et al. mtDNA copy number associated with age of onset in familial amyloid polyneuropathy. J Neurol Neurosurg Psychiatry. 2018;89:300\u20134.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"2243_CR28","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1136\/jnnp-2013-305383","volume":"85","author":"C Lemos","year":"2014","unstructured":"Lemos C, Coelho T, Alves-Ferreira M, Martins-da-Silva A, Sequeiros J, Mendon\u00e7a D, et al. Overcoming artefact: anticipation in 284 Portuguese kindreds with familial amyloid polyneuropathy (FAP) ATTRV30M. J Neurol Neurosurg Psychiatry. 2014;85:326\u201330.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"2243_CR29","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1080\/13506129.2018.1534731","volume":"25","author":"S Andreou","year":"2018","unstructured":"Andreou S, Panayiotou E, Michailidou K, Pirpa P, Hadjisavvas A, El Salloukh A, et al. Epidemiology of ATTRV30M neuropathy in Cyprus and the modifier effect of complement C1q on the age of disease onset. Amyloid. 2018;25:220\u20136.","journal-title":"Amyloid"},{"key":"2243_CR30","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1136\/jmg.30.5.388","volume":"30","author":"U Drugge","year":"1993","unstructured":"Drugge U, Andersson R, Chizari F, Danielsson M, Holmgren G, Sandgren O, et al. Familial amyloidotic polyneuropathy in Sweden: a pedigree analysis. J Med Genet. 1993;30:388\u201392.","journal-title":"J Med Genet"},{"key":"2243_CR31","doi-asserted-by":"publisher","first-page":"748","DOI":"10.2169\/internalmedicine.34.748","volume":"34","author":"K Tashima","year":"1995","unstructured":"Tashima K, Ando Y, Tanaka Y, Uchino M, Ando M. Change in the age of onset in patients with familial amyloidotic polyneuropathy type I. Intern Med. 1995;34:748\u201350.","journal-title":"Intern Med"}],"container-title":["BMC Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12883-021-02243-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12883-021-02243-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12883-021-02243-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,22]],"date-time":"2021-05-22T04:22:19Z","timestamp":1621657339000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcneurol.biomedcentral.com\/articles\/10.1186\/s12883-021-02243-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,22]]},"references-count":31,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["2243"],"URL":"https:\/\/doi.org\/10.1186\/s12883-021-02243-3","relation":{},"ISSN":["1471-2377"],"issn-type":[{"value":"1471-2377","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,22]]},"assertion":[{"value":"1 April 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 May 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 May 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Institutional Review Board of the Faculty of Medicine, Chulalongkorn University. Written informed consent to participate was obtained from all included patients.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent was obtained from all patients for the publication of this article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors have no conflicts of interest to declare.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"206"}}